T Cell Lymphoma clinical trials at UC Irvine
1 research study open to eligible people
Showing trials for
A Study of Duvelisib in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL)
open to eligible people ages 18 years and up
This is a multi-center, parallel cohort, open-label, Phase 2 study of duvelisib, an oral dual inhibitor of PI3K-δ,γ, in patients with relapsed or refractory Peripheral T cell Lymphoma (PTCL).
Irvine, California and other locations
Last updated: